Renoprotective effects of clarithromycin via reduction of urinary MCP-1 levels in type 2 diabetic patients

Atsuhito Tone, Kenichi Shikata, Koichi Nakagawa, Masaaki Hashimoto, Hirofumi Makino

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Recent studies have shown the involvement of microinflammation in the pathogenesis of diabetic nephropathy. We previously demonstrated that erythromycin, one of the macrolides, ameliorated renal injury via anti-inflammatory effects in experimental diabetic rats. We conducted an open randomized controlled pilot study to investigate the renoprotective effect of clarithromycin for diabetic nephropathy in type 2 diabetic patients manifesting albuminuria. Methods: Sixteen patients were randomly assigned to the control (n = 8) or the CAM group in which they received 200 mg/day of clarithromycin (n = 8). At the beginning of the study and after 3 months of investigation, the following parameters were assessed: urinary albumin creatinine ratio (ACR), the levels of serum MCP-1, soluble ICAM-1, IL-18, IL-6 and hs-CRP, and the levels of urinary MCP-1 and IL-18. Results: The changes in urinary ACR were significantly improved (P = 0.039), and serum creatinine levels showed a decreasing trend (P = 0.053) in the CAM group compared with the control group. Urinary MCP-1 levels were significantly reduced in the clarithromycin-administrated group (P = 0.009). However, there was no significant difference in other proinflammatory markers. A significant positive correlation was obtained between the post-to-pre-urinary ACR and the post-to-pre-urinary MCP-1 ratio(r = 0.526, P = 0.043). In the CAM group, the changes of serum creatinine also showed a significant positive correlation with those of urinary ACR, urinary MCP-1, urinary IL-18 and serum levels of soluble ICAM-1. Conclusion: The results from our study suggest that clarithromycin may attenuate the production of renal MCP-1 in type 2 diabetic patients, resulting in amelioration of urinary ACR via anti-inflammatory effects. Modulation of microinflammation with clarithromycin may provide a new approach for diabetic nephropathy.

Original languageEnglish
Pages (from-to)79-85
Number of pages7
JournalClinical and Experimental Nephrology
Volume15
Issue number1
DOIs
Publication statusPublished - Feb 2011

Fingerprint

Clarithromycin
Creatinine
Albumins
Interleukin-18
Diabetic Nephropathies
Intercellular Adhesion Molecule-1
Serum
Anti-Inflammatory Agents
Kidney
Albuminuria
Macrolides
Erythromycin
Interleukin-6
Control Groups
Wounds and Injuries

Keywords

  • Clarithromycin
  • Diabetic nephropathy
  • Macrolide
  • MCP-1
  • Microinflammation

ASJC Scopus subject areas

  • Nephrology
  • Physiology
  • Physiology (medical)

Cite this

Renoprotective effects of clarithromycin via reduction of urinary MCP-1 levels in type 2 diabetic patients. / Tone, Atsuhito; Shikata, Kenichi; Nakagawa, Koichi; Hashimoto, Masaaki; Makino, Hirofumi.

In: Clinical and Experimental Nephrology, Vol. 15, No. 1, 02.2011, p. 79-85.

Research output: Contribution to journalArticle

@article{7dae8fedd93b41a4b7a07bbd27682ac8,
title = "Renoprotective effects of clarithromycin via reduction of urinary MCP-1 levels in type 2 diabetic patients",
abstract = "Background: Recent studies have shown the involvement of microinflammation in the pathogenesis of diabetic nephropathy. We previously demonstrated that erythromycin, one of the macrolides, ameliorated renal injury via anti-inflammatory effects in experimental diabetic rats. We conducted an open randomized controlled pilot study to investigate the renoprotective effect of clarithromycin for diabetic nephropathy in type 2 diabetic patients manifesting albuminuria. Methods: Sixteen patients were randomly assigned to the control (n = 8) or the CAM group in which they received 200 mg/day of clarithromycin (n = 8). At the beginning of the study and after 3 months of investigation, the following parameters were assessed: urinary albumin creatinine ratio (ACR), the levels of serum MCP-1, soluble ICAM-1, IL-18, IL-6 and hs-CRP, and the levels of urinary MCP-1 and IL-18. Results: The changes in urinary ACR were significantly improved (P = 0.039), and serum creatinine levels showed a decreasing trend (P = 0.053) in the CAM group compared with the control group. Urinary MCP-1 levels were significantly reduced in the clarithromycin-administrated group (P = 0.009). However, there was no significant difference in other proinflammatory markers. A significant positive correlation was obtained between the post-to-pre-urinary ACR and the post-to-pre-urinary MCP-1 ratio(r = 0.526, P = 0.043). In the CAM group, the changes of serum creatinine also showed a significant positive correlation with those of urinary ACR, urinary MCP-1, urinary IL-18 and serum levels of soluble ICAM-1. Conclusion: The results from our study suggest that clarithromycin may attenuate the production of renal MCP-1 in type 2 diabetic patients, resulting in amelioration of urinary ACR via anti-inflammatory effects. Modulation of microinflammation with clarithromycin may provide a new approach for diabetic nephropathy.",
keywords = "Clarithromycin, Diabetic nephropathy, Macrolide, MCP-1, Microinflammation",
author = "Atsuhito Tone and Kenichi Shikata and Koichi Nakagawa and Masaaki Hashimoto and Hirofumi Makino",
year = "2011",
month = "2",
doi = "10.1007/s10157-010-0357-1",
language = "English",
volume = "15",
pages = "79--85",
journal = "Clinical and Experimental Nephrology",
issn = "1342-1751",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - Renoprotective effects of clarithromycin via reduction of urinary MCP-1 levels in type 2 diabetic patients

AU - Tone, Atsuhito

AU - Shikata, Kenichi

AU - Nakagawa, Koichi

AU - Hashimoto, Masaaki

AU - Makino, Hirofumi

PY - 2011/2

Y1 - 2011/2

N2 - Background: Recent studies have shown the involvement of microinflammation in the pathogenesis of diabetic nephropathy. We previously demonstrated that erythromycin, one of the macrolides, ameliorated renal injury via anti-inflammatory effects in experimental diabetic rats. We conducted an open randomized controlled pilot study to investigate the renoprotective effect of clarithromycin for diabetic nephropathy in type 2 diabetic patients manifesting albuminuria. Methods: Sixteen patients were randomly assigned to the control (n = 8) or the CAM group in which they received 200 mg/day of clarithromycin (n = 8). At the beginning of the study and after 3 months of investigation, the following parameters were assessed: urinary albumin creatinine ratio (ACR), the levels of serum MCP-1, soluble ICAM-1, IL-18, IL-6 and hs-CRP, and the levels of urinary MCP-1 and IL-18. Results: The changes in urinary ACR were significantly improved (P = 0.039), and serum creatinine levels showed a decreasing trend (P = 0.053) in the CAM group compared with the control group. Urinary MCP-1 levels were significantly reduced in the clarithromycin-administrated group (P = 0.009). However, there was no significant difference in other proinflammatory markers. A significant positive correlation was obtained between the post-to-pre-urinary ACR and the post-to-pre-urinary MCP-1 ratio(r = 0.526, P = 0.043). In the CAM group, the changes of serum creatinine also showed a significant positive correlation with those of urinary ACR, urinary MCP-1, urinary IL-18 and serum levels of soluble ICAM-1. Conclusion: The results from our study suggest that clarithromycin may attenuate the production of renal MCP-1 in type 2 diabetic patients, resulting in amelioration of urinary ACR via anti-inflammatory effects. Modulation of microinflammation with clarithromycin may provide a new approach for diabetic nephropathy.

AB - Background: Recent studies have shown the involvement of microinflammation in the pathogenesis of diabetic nephropathy. We previously demonstrated that erythromycin, one of the macrolides, ameliorated renal injury via anti-inflammatory effects in experimental diabetic rats. We conducted an open randomized controlled pilot study to investigate the renoprotective effect of clarithromycin for diabetic nephropathy in type 2 diabetic patients manifesting albuminuria. Methods: Sixteen patients were randomly assigned to the control (n = 8) or the CAM group in which they received 200 mg/day of clarithromycin (n = 8). At the beginning of the study and after 3 months of investigation, the following parameters were assessed: urinary albumin creatinine ratio (ACR), the levels of serum MCP-1, soluble ICAM-1, IL-18, IL-6 and hs-CRP, and the levels of urinary MCP-1 and IL-18. Results: The changes in urinary ACR were significantly improved (P = 0.039), and serum creatinine levels showed a decreasing trend (P = 0.053) in the CAM group compared with the control group. Urinary MCP-1 levels were significantly reduced in the clarithromycin-administrated group (P = 0.009). However, there was no significant difference in other proinflammatory markers. A significant positive correlation was obtained between the post-to-pre-urinary ACR and the post-to-pre-urinary MCP-1 ratio(r = 0.526, P = 0.043). In the CAM group, the changes of serum creatinine also showed a significant positive correlation with those of urinary ACR, urinary MCP-1, urinary IL-18 and serum levels of soluble ICAM-1. Conclusion: The results from our study suggest that clarithromycin may attenuate the production of renal MCP-1 in type 2 diabetic patients, resulting in amelioration of urinary ACR via anti-inflammatory effects. Modulation of microinflammation with clarithromycin may provide a new approach for diabetic nephropathy.

KW - Clarithromycin

KW - Diabetic nephropathy

KW - Macrolide

KW - MCP-1

KW - Microinflammation

UR - http://www.scopus.com/inward/record.url?scp=79952184907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952184907&partnerID=8YFLogxK

U2 - 10.1007/s10157-010-0357-1

DO - 10.1007/s10157-010-0357-1

M3 - Article

C2 - 21042828

AN - SCOPUS:79952184907

VL - 15

SP - 79

EP - 85

JO - Clinical and Experimental Nephrology

JF - Clinical and Experimental Nephrology

SN - 1342-1751

IS - 1

ER -